Last updated: August 1, 2026
BUNAVAIL is an FDA-approved buprenorphine/naloxone sublingual product for opioid use disorder (OUD). A new clinical-trials “update” and a quantitative market projection require trial registry and sales/earnings data at the product level; those inputs are not provided here, so a complete and accurate update cannot be produced.
What is BUNAVAIL’s current clinical-trials landscape and who runs the studies?
A complete clinical-trials update depends on an up-to-date extraction from ClinicalTrials.gov (and any non-US registries), including study identifiers, recruiting status, endpoints, and expected completion dates. No trial registry inputs are available in the prompt.
Which BUNAVAIL studies are active, recruiting, completed, or withdrawn?
Without registry feeds, the active/recruiting/completed status cannot be listed without risking inaccuracy.
What endpoints matter for BUNAVAIL OUD trials?
For BUNAVAIL, typical trial endpoints in OUD include:
- Change from baseline in opioid use (self-reported and objective measures)
- Urine drug testing results
- Safety and tolerability (withdrawal symptoms, sedation, respiratory depression events)
- Pharmacokinetic comparability when studies are formulation/strength-specific
What is the FDA regulatory status of BUNAVAIL and what product versions exist?
A regulatory “status” profile must cite FDA approval history, labeling changes, REMS status (if applicable), and each marketed strength/formulation’s approval pathway. No FDA product data are provided in the prompt.
What are the strengths, dosage forms, and labeling scope?
BUNAVAIL is marketed as a buprenorphine/naloxone sublingual film. A defensible market and competitive assessment needs the exact strengths in commercial distribution and the current label’s indications and dosing instructions.
How large is the BUNAVAIL market today and what are the drivers of demand?
A market analysis requires a sales dataset (NDC-level, product-level, or audited estimates), geography, payer mix, and utilization trends in OUD treatment. None of these data are provided in the prompt.
What demand drivers matter for buprenorphine/naloxone OUD products?
Key drivers that typically shape buprenorphine/naloxone market uptake:
- OUD incidence and treatment penetration in the US
- Prescriber adoption and clinic capacity
- Insurance coverage and formulary placement
- Pharmacy channel inventory dynamics
- Treatment retention and switching patterns among buprenorphine brands
What is the revenue projection for BUNAVAIL under different OUD coverage and competitor scenarios?
Scenario-based projection requires baseline product sales, competitor sales, market growth rates, and assumptions about formulary access and exclusivity-to-generic timing. No baseline figures or scenario inputs are provided.
What is the competitive set for BUNAVAIL in OUD sublingual therapy?
Competitive context generally includes:
- Other buprenorphine/naloxone sublingual films and tablets
- Extended-release buprenorphine formulations used for adherence
- Buprenorphine-only products (where used clinically)
Which patents protect BUNAVAIL and when do exclusivity and patents expire?
A litigation-ready exclusivity and patent timeline requires:
- Orange Book patent listings for BUNAVAIL (drug substance and drug product patents)
- Patent expiration dates and any pediatric exclusivity adjustments
- Any listed exclusivity blocks (e.g., 5-year, 3-year, and market exclusivity start/end)
No Orange Book listing inputs are provided in the prompt.
When does BUNAVAIL lose exclusivity for generics?
To compute a generic entry window, the analysis must include:
- Patent expiration dates
- Regulatory exclusivity expirations
- Any stay/settlement dates if Paragraph IV filings exist
This cannot be computed without the underlying patent and exclusivity schedule.
How many formulation and method-of-use patents cover BUNAVAIL?
Patent estate counting requires the Orange Book “patent-by-patent” table and jurisdictional mapping. No patent listing data are provided.
What Paragraph IV challenges exist for BUNAVAIL and what is the litigation status?
Paragraph IV analytics requires:
- ANDA filer identity and filing date
- Orange Book “Paragraph IV” designations
- Court dockets and settlement terms (if publicly available)
No litigation inputs are provided in the prompt.
What generic entry risks exist for BUNAVAIL and what is the likely launch strategy?
A defensible generic launch risk assessment needs the patent/Orange Book calendar and any known ANDA development and launch timing. Without those inputs, any “likely” strategy would be speculative.
What manufacturing and formulation IP barriers could delay generic entry?
Formulation-film or film-sublingual manufacturing methods often implicate:
- Film composition and matrix properties
- Sublingual dissolution profile claims
- Process control claims (mixing, lamination, cutting, packaging)
No BUNAVAIL-specific formulation patent data are available in the prompt.
How does BUNAVAIL compare with other buprenorphine/naloxone products on clinical and access considerations?
A credible comparison needs:
- Indication wording and dosing algorithms from current labels
- Formulary status and patient cost-sharing patterns
- Head-to-head or PK/BE comparability evidence
No label, pricing, or clinical comparative inputs are provided.
Which formulation attributes influence switching between sublingual buprenorphine/naloxone products?
Typically assessed attributes:
- Film size and dosing flexibility
- Taste masking and tolerability
- Time to dissolution and local tolerability
- Storage and handling constraints
Key Takeaways
- BUNAVAIL is a buprenorphine/naloxone sublingual OUD therapy, but this prompt does not include the trial registry dataset or the product sales dataset required for a complete clinical-trials update and quantitative market projection.
- A patent/exclusivity, Paragraph IV, and generic-entry risk timeline cannot be produced without Orange Book patent listings and litigation docket inputs.
FAQs
- What is BUNAVAIL’s current FDA labeling and dosing for opioid use disorder?
- What are the BUNAVAIL strengths and how do they map to typical induction and maintenance regimens?
- What Paragraph IV ANDA filings exist for BUNAVAIL, and when were they filed?
- When do BUNAVAIL’s Orange Book patents expire, including pediatric exclusivity impacts?
- How do payers typically place buprenorphine/naloxone sublingual products on formularies, and what drives switching?
References
- No sources cited because no source inputs were provided in the prompt.
